Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas.
Chiappa M, Decio A, Guarrera L, Mengoli I, Karki A, Yemane D, Ghilardi C, Scanziani E, Canesi S, Barbera MC, Craparotta I, Bolis M, Fruscio R, Grasselli C, Ceruti T, Zucchetti M, Patterson JC, Lu RA, Yaffe MB, Ridinger M, Damia G, Guffanti F. Chiappa M, et al. Among authors: ridinger m. Cell Death Dis. 2024 Jul 22;15(7):521. doi: 10.1038/s41419-024-06894-1. Cell Death Dis. 2024. PMID: 39039067 Free PMC article.
Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas.
Affatato R, Chiappa M, Guffanti F, Ricci F, Formenti L, Fruscio R, Jaconi M, Ridinger M, Erlander M, Damia G. Affatato R, et al. Among authors: ridinger m. Ther Adv Med Oncol. 2022 May 31;14:17588359221095064. doi: 10.1177/17588359221095064. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35665077 Free PMC article.
Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.
Patterson JC, Varkaris A, Croucher PJP, Ridinger M, Dalrymple S, Nouri M, Xie F, Varmeh S, Jonas O, Whitman MA, Chen S, Rashed S, Makusha L, Luo J, Isaacs JT, Erlander MG, Einstein DJ, Balk SP, Yaffe MB. Patterson JC, et al. Among authors: ridinger m. Cancer Res. 2023 Jan 18;83(2):219-238. doi: 10.1158/0008-5472.CAN-22-1533. Cancer Res. 2023. PMID: 36413141 Free PMC article.
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.
Ahn DH, Ridinger M, Cannon TL, Mendelsohn L, Starr JS, Hubbard JM, Kasi A, Barzi A, Samuëlsz E, Karki A, Subramanian RA, Yemane D, Kim R, Wu CC, Croucher PJP, Smeal T, Kabbinavar FF, Lenz HJ. Ahn DH, et al. Among authors: ridinger m. J Clin Oncol. 2024 Oct 30:JCO2401266. doi: 10.1200/JCO-24-01266. Online ahead of print. J Clin Oncol. 2024. PMID: 39475591
Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α1-blockers.
Wang X, Li B, Ciotkowska A, Rutz B, Erlander MG, Ridinger M, Wang R, Tamalunas A, Waidelich R, Stief CG, Hennenberg M. Wang X, et al. Among authors: ridinger m. Eur J Pharmacol. 2020 Apr 15;873:172985. doi: 10.1016/j.ejphar.2020.172985. Epub 2020 Feb 1. Eur J Pharmacol. 2020. PMID: 32017934
PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights.
Sreekumar S, Montaudon E, Klein D, Gonzalez ME, Painsec P, Derrien H, Sourd L, Smeal T, Marangoni E, Ridinger M. Sreekumar S, et al. Among authors: ridinger m. Cancers (Basel). 2024 Sep 25;16(19):3259. doi: 10.3390/cancers16193259. Cancers (Basel). 2024. PMID: 39409880 Free PMC article.
50 results